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AbstrACt
Introduction Treatment of acute stroke has drastically 
changed in the last 10 years. Endovascular therapy is now 
the standard of care for patients with a stroke caused by 
a large vessel occlusion in the anterior circulation. The 
impact of the type of anaesthesia (general anaesthesia 
or conscious sedation) during endovascular therapy on 
the outcome of the patients is still a matter of debate. 
Previous studies are mostly retrospective and/or focused 
on the early postprocedure outcome and/or without blood 
pressure goals and/or single-centre small size studies. We 
therefore designed a multicentre study hypothesising that 
conscious sedation is associated with a better functional 
outcome 3 months after endovascular therapy for the 
treatment of stroke compared with general anaesthesia.
Methods/analysis The General Anesthesia vs Sedation 
for Stroke (GASS) Trial is a randomised, parallel, single-
blind, multicentre study of 350 patients undergoing 
endovascular therapy for the treatment of stroke. Patients 
will be randomly allocated to receive either a general 
anaesthesia or a conscious sedation. The primary outcome 
measure is the modified Rankin score assessed 3 months 
after the treatment. Data will be analysed on the intention-
to-treat principle.
Ethics/dissemination The GASS Trial has been approved 
by an independent ethics committee for all study centres. 
Participant recruitment begins in September 2016. Results 
will be published in international peer-reviewed medical 
journals.
trial registration number NCT02822144.
IntroduCtIon
The treatment of acute stroke has been 
recently transformed with the publication 
of randomised controlled trials (RCTs) 
showing the benefit of endovascular therapy 
when compare with the medical treatment 
in terms of functional outcome.1–4 Endovas-
cular therapy in addition to the medical treat-
ment is now the standard of care for selected 
patients who had a stroke caused by a large 
vessel occlusion in the anterior circulation. 
All studies have highlighted that the rapidity 
of the treatment is an essential factor for a 
good outcome. The other important factor 
is the haemodynamic conditions during the 
procedure because instability can worsen 
the clinical outcome.5 6 A retrospective study 
concluded that a change of even 10% in 
mean arterial pressure almost quadrupled 
the risk for poor outcomes.7 
In this context, the best anaesthetic strategy 
during the endovascular treatment has not 
been yet defined. Indeed, the choice between 
general anaesthesia (GA) and conscious seda-
tion (CS) remains unclear. While allowing 
immobility, cerebral protection and airway 
control, GA can delay the endovascular treat-
ment. However, CS is more rapid, allows neuro-
logical assessment during the procedure but 
the thrombectomy can be more difficult for 
the neuroradiologist because of patients’ move-
ments. In terms of haemodynamic stability, 
strengths and limitations of this study
 ► GASS Trial is a randomised, parallel, single-blind, 
multicentre study comparing the effects of general 
anaesthesia and conscious sedation during endo-
vascular therapy for stroke.
 ► GASS Trial is focused on the functional outcome of 
the patients 3 months after the treatment.
 ► The multicentre design, broad inclusion criteria, 
large sample size (350 patients) and follow-up will 
support external validity.
 ► The study does not include a systemic CT scan after 
the endovascular treatment.
 ► The sizing of the stroke is also not part of the study 
as it is newly implemented technology.
 o
n
 Septem
ber 4, 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024249 on 1 June 2019. Downloaded from 
2 Maurice A, et al. BMJ Open 2019;9:e024249. doi:10.1136/bmjopen-2018-024249
Open access 
retrospective studies reported results favouring CS.8–10 
However, these studies did not focus on the anaesthetic 
protocol and the intraprocedure haemodynamic. Anaes-
thetic protocols were not standardised. The first RCT on 
the subject was published in 2016.11 This monocentric study 
did not find any benefit of CS over GA in terms of outcome 
24 hours and 3 months after the treatment. However, func-
tional outcome at 3 months was only a secondary outcome, 
and the anaesthesia protocol was not detailed. Moreover, 
the design allowed patients in the CS group to receive anal-
gesics and/or sedatives if necessary, which could then trans-
form a CS into a light GA. Löwhagen Hendén et al12 did also 
not show any difference between the two anaesthetic tech-
nics using a well-described anaesthesia protocol. However, 
the study included only 90 patients and was monocentric. 
The most recent study13 using an identical design with 
infarct growth as the primary endpoint reported no differ-
ences between CS and GA. Clinical outcome at 90 days, 
tested as a secondary endpoint, was better in the GA group. 
Finally, a meta-analysis analysing the pooled data of seven 
trials14 reported that worse outcomes at 3 months were asso-
ciated with GA. However, the choice to treat a patient with 
or without GA was not randomised in the trials included in 
this meta-analysis.14
So far, few studies has assessed the clinical outcome 3 
months after the stroke treatment comparing GA and 
CS using standardised anaesthetic protocols and tight 
haemodynamic control. Indeed, in previous studies,11–13 
the anaesthesia protocol was either not standardised 
or the doses not given, the blood pressure (BP) was 
controlled with vasoactives drugs as different as dopamine 
and norepinephrine in the same study and the clinical 
outcome 3 months after the stroke was not the primary 
objective of one study.13 The recently published post hoc 
analysis of the Sedation vs Intubation for Endocascular 
Stroke Treatment (SIESTA) trial15 and the General or 
Local Anesthesia in Intra-Arterial Therapy (GOLIATH) 
trial16 reported no association between heamodynamic 
variations and National Institute of Health Stroke Score 
(NIHSS) change after 24 hours.
Therefore, we designed an RCT comparing GA and CS 
during endovascular treatment for acute stroke. Both GA 
and CS protocols will be standardised and the control of 
arterial BP too. We hypothesised that CS will be associated 
with a better clinical outcome measured with the modified 
Rankin score (mRS) 3 months after the procedure. The 
General Anesthesia vs Sedation for Stroke(GASS) study is 
the first multicentric RCT including a detailed anaesthesia 
protocol with a tight haemodynamic control, comparing 
GA and CS during endovascular treatment (EVT) and eval-
uating the functional outcome at 3 months.
MEthods And AnAlysIs
trial design
The GASS study is an investigator-initiated, national, multi-
centre, randomised, simple-blind, parallel-group clinical 
trial with concealed allocation of patients scheduled to 
undergo endovascular therapy for stroke 1:1 to receive 
either a GA protocol or a CS protocol. The trial will be 
conducted in four university and non-university centres. 
It started in September 2016 and will continue for a total 
of 36 months.
Participant eligibility and consent
Trial site investigators will identify consecutive eligible 
patients from the listed criteria. Eligible patients or a 
family member when appropriate will receive written and 
oral information and will be included after investigators 
have obtained informed written consent.
Inclusion criteria
1. Adult (18 years or older) patients admitted to the par-
ticipating centre.
2. Occlusion of a large vessel in the anterior cerebral cir-
culation.
3. Undergoing endovascular therapy for stroke.
4. Benefiting from the health insurance system.
5. Signed informed consent from the patient or their le-
gally next of kin.
Non-inclusion criteria
1. Pregnant or breastfeeding women.
2. Patients already intubated and mechanical ventilated 
before inclusion in the study.
3. Intracerebral haemorrhage associated with the isch-
aemic stroke.
4. Contraindications to CS: Glasgow coma scale inferi-
or to 8, agitation not allowing the patient to stay still 
during the procedure and deglutition disorders.
5. Contraindications to succinylcholine: hyperkalaemia 
and allergy.
6. Body mass index superior to 35 kg/m2.
7. Allergy to one of the anaesthetic drugs.
8. Uncontrolled hypotension.
9. Life-threatening comorbidity.
10. Adults legally protected (under judicial protection, 
guardianship or supervision) and persons deprived 
of their liberty.
11. Patients who could not walk prior stroke.
Allocation and blinding
Patients will be randomised in two groups (GA group and 
CS group). Randomisation will be done by investigators 
as close as possible to the endovascular therapy. Each 
patient will be given a unique randomisation number 
(patient code). Randomisation will be stratified on the 
centre, the National Institute of Health Stroke Score 
(NIHSS ≤14 or >14) and the administration or not of 
intravenous thrombolysis. The primary evaluation crite-
rion will be assessed blinded to the randomisation group. 
During the study period, outcome assessors will be kept 
blind to the randomisation group. Research nurses evalu-
ating the outcomes 3 months after the treatment will not 
participate to the anaesthesia and will not be aware of the 
randomisation group. They will be blinded to the treat-
ment. The anaesthesiologist, the nurse anaesthesiologist, 
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the neuroradiologist and the neurologist will not be 
blinded. They will not participate in the assessment of the 
patients at any time.
At each participating centre, data will be collected 
and entered into the electronic web-based case report 
form (eCRF) by trial or clinical trained personal (clin-
ical research associate), blinded to the allocation group, 
under the supervision of the trial site investigators.
Interventions
All included patients will be allocated to one of the 
following two study groups:
 ► GA group: patients will receive a standardised anaes-
thesia protocol with remifentanil.
 ► CS group: patients will receive a standard CS with 
remifentanil.
Standardised GA will include: Induction: etomidate 
(0.25–0.4 mg/kg) and succinylcholine (1 mg/kg) and 
maintenance: TCI propofol (maximum target: 4 µg/mL), 
TCI remifentanil (0.5–4 ng/mL) and curares as needed.
Standardised CS will include: Target controlled infusion 
(TCI) remifentanil (maximum target 2 ng/mL), local 
anaesthesia with lidocaine 10 mg/mL (maximum 10 mL). 
Oxygen will be administered only if SPO2 ≤96%. Respira-
tory rate and capnography will be monitored.
CS can be converted into a GA in the following 
situations:
 ► Agitation or restlessness not allowing the endovas-
cular therapy.
 ► Vomiting not allowing the endovascular therapy.
 ► Glasgow Coma Scale <8 and/or deglutition disorders.
 ► Severe hypoxaemia with SPO2 <96% with oxygen 
delivered with a high concentration mask (10 L/min 
maximum).
 ► Respiratory depression with respiratory rate >35/ min 
and/or clinical signs of respiratory exhaustion.
In both groups: intraoperative dose changes will be left 
to the anaesthesiologist in charge of the patient if neces-
sary, intravenous norepinephrine will be administered in 
order to maintain BP within the recommended range: 
systolic blood pressure (SBP) between 140 mm Hg and 
185 mm Hg; diastolic blood pressure (DBP) <110 mm 
Hg. A drop of more than 25% of the mean blood pres-
sure (MBP) will also be avoided. BP will be continuously 
non-invasively monitored. Norepinephrine will be admin-
istered in a dedicated intravenous line and diluted at 250 
µg/mL. Hyperglycaemia will be treated with intravenous 
insulin when necessary (target 11 mmol/L).
A systematic immediate post-EVT Cone-beam CT scan 
will be performed for all patients.
Decisions about all other aspects of patient care will 
be performed according to the expertise of the staff 
at each centre and to routine clinical practice to mini-
mise interference with the trial intervention. Postop-
erative BP targets are defined as follows: SBP <180 mm 
Hg, DBP <110 mm Hg and MBP >65 mm Hg. In case of 
tretament in cerabral ischemia scale (TICI) 2a or lower, 
the objective is MBP >75 mm Hg. Norepinephrine will be 
used if necessary. Three months after the thrombectomy, 
patients will consult with a neurologist.
outcome measures
Primary outcome measure
The primary outcome measure will be the neurological 
outcome assessed with the mRS 3 months17 after the 
endovascular therapy. Success will be considered as an 
mRS ≤2. The mRS will be assessed by trained research 
nurse blinded to the randomisation group.
An additional exploratory analysis of the primary 
endpoint will be performed to assess treatment effects 
according to baseline NIHSS (≤14 or >14) and the admin-
istration or not of intravenous thrombolysis.
Secondary outcomes measures
 ► Time between the beginning of the clinical symptoms 
and the last angiography.
 ► Time between the arrival of the patient at the stroke 
centre and the beginning of the endovascular therapy 
(time of punction).
 ► Quality of the recanalisation after the endovascular 
treatment evaluated by the neuroradiologist (not 
blinded). A good quality recanalisation corresponds 
to a 2b or 3 mTICI (modified treatment in cerebral 
ischaemia scale).18
 ► NIHSS score at day 1 (day after the endovascular 
treatment) and day 7 (or the day the patient leaves 
the hospital if scheduled before D7).19
 ► Complications during the procedure (dissection, 
rupture of the artery and thrombus in another 
territory).
 ► Mortality rate 3 months after the endovascular 
treatment.
 ► Number of hypotension or hypertension events 
during the procedure and the first 24 hours after the 
procedure (hypotension defined as SBP <140 mm Hg 
or a drop of the MBP of 40% or more, hypertension 
defined as SBP >185 mm Hg or DBP >110 mm Hg).
 ► Number of patients who received norepinephrine.
 ► Number of conversion of CS to GA.
statistical analysis
Statistical analysis will be performed on all randomised 
and evaluated patients (intention-to-treat analysis). It will 
be performed with SAS software, version 9, in the Method-
ology/Biometrics department of the Inserm 1414 Clinical 
Investigation Centre of Rennes. A first overall descriptive 
analysis and analysis by group will be performed. This 
consists of separate estimates, numbers and percentages 
for qualitative variables, means, SE, medians and inter-
quartile intervals for quantitative variables. The normal 
feature of the distribution of quantitative variables will 
be checked. Student’s t-test or a Mann-Whitney U test, if 
necessary, will be used to compare quantitative variables, 
and a χ2 or Fisher’s exact test, if necessary, will be used to 
compare qualitative variables between two groups at inclu-
sion. The primary endpoint will be compared between 
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the two groups with the χ 2 test. Two interim analyses after 
inclusion of 1/3 and 2/3 of the patients and one final 
analysis are planned. Stopping rules will use the alpha 
spending function with the O’Brien-Fleming boundary. 
The cumulative values of alpha for each analysis are: 
0.00021 at the first analysis, 0.01202 at the second analysis 
and 0.04626 at the final analysis (nTerim, V.1.1, Statistical 
solutions Ltd, Cork, Ireland). The trial will be stopped 
early if the significance of the χ 2 test is below these 
alpha values. For the analysis of the other endpoints, the 
same strategy as for baseline comparisons will be used. 
Continuous endpoints repeatedly measured during the 
study will be compared using a repeated measure two-way 
(time and group) analysis of variance. For all these anal-
yses, adjustments can be made in case of heterogeneity 
at inclusion. Except for the interim analyses, a p value 
<0.05 will be considered as significant for all analyses.
Missing values
Missing data will not be replaced. Mixed models can be 
used in analysis of repeated data to avoid deleting subjects 
with any missing values.
sample size estimation
A previous study reported 30% of the patients with an 
mRS score of ≤2 after endovascular therapy under GA.20 
We aim to show an increase of patients with a good prog-
nostic (defined as mRS ≤2) up to 45% after endovascular 
treatment under CS. Therefore, 166 patients per group 
will be needed to have 80% power at a two-sided alpha 
level of 0.05. A total of 350 patients will be included to 
take into account non-evaluable patients and drop outs.
data registration
Data will be entered into the web-based eCRF by trial or 
clinical personnel under the supervision of the trial site 
investigators at each participating centre. From the eCRF, 
the trial database will be established. Data collection will 
be monitored by trained research coordinators.
The following data will be registered:
Baseline characteristics at randomisation
Demographic data (age, height, weight, gender and 
body mass index); American Society of Anesthesiologists 
physical status; significant comorbidities (cardiovascular, 
respiratory, neurological, psychiatric and/or abdominal 
disease, cancer, preoperative chemotherapy or radio-
therapy), NIHSS score, time of arrival at the hospital, 
time of the beginning of the symptoms, time of the cere-
bral angiography or MRI (meaning time of first image for 
diagnosis), time between the first contact of the patient 
with the anaesthesiologist and the induction of anaes-
thesia (GA or CS), localisation of the stroke, intravenous 
fibrinolysis if applicable, creatinine clearance and haemo-
stasis (PT and ACT if available).
Intraoperative data
Time of arterial puncture, time of recanalisation, 
mTICI score,16 doses of norepinephrine, intraoperative 
complications (hypotension defined as SBP <140 mm 
Hg or a drop of the MBP of 40% or more, hypertension 
defined as SBP >185 mm Hg or DBP >110 mm Hg) neces-
sity to convert the CS onto a GA, duration of anaesthesia 
and procedure, procedure-related complications (distal 
embolisation in a different territory, intramural arterial 
dissection, arterial perforation and access site complica-
tions leading to surgery).
Postoperative data
The following data will be collected:
 ► Duration of invasive ventilation.
 ► NIHSS day 1 and day 7 or the day the patient leaves 
the hospital if before day 7.
 ► Necessity of norepinephrine during the first 2 hours 
after the endovascular treatment.
 ► Hypotension or hypertension events as defined above 
during first 24 hours.
 ► Bradycardia with atropine treatment during first 
24 hours.
 ► Hospitalisation in intensive care unit.
 ► Number of hours of invasive ventilation.
 ► Pneumonia.
 ► Death until the final call for mRS (3 months after the 
procedure).
 ► mRS 3 months after the procedure during a tele-
phone interview.21
Patient withdrawal
A participant who no longer agrees to participate in the 
clinical trial can withdraw the informed consent at any time 
without need of further explanation. Participants who will 
withdraw from the study will be followed up, according to 
routine clinical practice in each participating centre. In 
order to conduct intention-to-treat analyses with as little 
missing data as possible, the investigator may ask the partic-
ipant which aspects of the trial he or she wishes to withdraw 
from (participation in the remaining follow-up assessments 
and use of already collected data). Whenever possible, the 
participant will be asked for permission to obtain data for the 
primary outcome measure. All randomised patients will be 
reported, and all data available with consent will be used in 
the analyses. If appropriate, missing data will be handled in 
accordance with multiple imputation procedures if missing 
data are greater than 5%.
Safety
Every serious adverse event related to the studied treatment 
or not, expected or unexpected, will be reported within 
24 hours by the investigator to the sponsor on a ‘Serious 
adverse event’ form on which will be indicated the date of 
occurrence, criterion of severity, intensity, relationship with 
the treatment (or the study) evaluated and the outcome. 
The period in which serious adverse events should be 
reported begins from the day of the written informed 
consent to the end of the follow-up (day of the evaluation 
of mRS 3–4 months after the procedure). Whenever a 
serious adverse event persists at the end of the study, the 
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investigator will follow the patient until the event is consid-
ered resolved. The following events: hypotension or hyper-
tension will be recorded as study endpoints criterion in the 
case report form. In order to avoid collection duplication, 
they will not be reported on the ‘adverse event’ page of the 
case report form. As planned in the study, they will be anal-
ysed at the time of interim analyses (two interim analyses 
after inclusion of 1/3 and 2/3 of the patients), which will 
permit to show potential difference between the two groups 
during the study.
In addition, serious adverse events will be submitted to 
the data monitoring and safety committee (DMSC). The 
DMSC is independent of the trial investigators and will 
perform an ongoing review of safety parameters and overall 
study conduct. The DMSC is composed of a neurologist, 
an anaesthesiologist, a neuroradiologist, a pharmacologist 
and a methodologist. The DMSC will be responsible for 
safeguarding the interests of trial participants, assessing 
the safety and efficacy of the interventions during the trial 
and for monitoring the overall conduct of the clinical trial. 
To contribute to enhancing the integrity of the trial, the 
DMSC may also formulate recommendations relating to 
the recruitment/retention of participants, their manage-
ment, improving adherence to protocol-specified regimens 
and retention of participants and the procedures for data 
management and quality control. Recommendations for 
pausing or stopping the study will be made by the DMSC in 
case of serious adverse reactions and suspected unexpected 
serious adverse reaction.
All adverse events for which the investigator or the 
sponsor considers that a causal relationship with the 
investigational medicinal products can be reasonably 
considered will be considered as suspected adverse reac-
tions. If they are unexpected, they are qualified as being 
suspected unexpected serious adverse events (SAR) and 
will be notified in a report by the sponsor to Eudravig-
ilance (European pharmacovigilance database) and 
to local regulatory agency within the regulatory time 
periods for reporting: immediate declaration if serious-
ness criteria is death or life-threatening condition, decla-
ration within 15 days for other seriousness criteria.
Data handling and retention
Data will be handled according to French law. All original 
records (including consent forms, reports of suspected 
unexpected serious adverse reactions and relevant corre-
spondences) will be archived at trial sites for 15 years. 
The clean trial database file will be anonymised and main-
tained for 15 years.
Patient and public involvement
Patient and public were not involved in any of the phases 
of this study
EthICs And dIssEMInAtIon
Ethical and legislative approvals
GASS Trial was approved by the French National Safety 
and Drug Agency (Agence Nationale de Sécurité du 
Médicament (8 September 2016). By 13 June 2016, the 
study has been approved for all centres by a central ethics 
committee (Comité de Protection des Personnes de 
Poitiers). The GASS Trial is registered in the European 
Clinical Trials Database (EudraCT 2016-000795-25) and 
at  ClinicalTrials. gov with the trial identification number 
NCT02822144. Trial methods and results will be reported 
according to the Consolidated Standards of Reporting 
Trials 2010 guidelines.22
Publication plan
Scientific presentations and reports corresponding to the 
study will be written under the responsibility of the coor-
dinating investigator of the study with the agreement of 
the principal investigators and the methodologist. The 
coauthors of the report and of publications will be the 
investigators and clinicians involved, on a pro rata basis 
of their contribution in the study, as well as the biostat-
istician and associated researchers. All trial sites will be 
acknowledged, and all investigators at these sites will 
appear with their names under ‘the GASS investigators’ 
in the final manuscript. Rules on publication will follow 
international recommendations.23
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